ISRCTN10166784已完成未知
A randomised controlled multi-centre open-label parallel-group non-inferiority trial of the clinical effectiveness, acceptability and cost-effectiveness of a ‘stepping into day treatment’ approach versus inpatient treatment as usual for anorexia nervosa in adult specialist eating disorder services
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 15
研究概览
简要总结
2022 Protocol article in https://pubmed.ncbi.nlm.nih.gov/35710394/ (added 17/06/2022) 2023 Results article in https://pubmed.ncbi.nlm.nih.gov/36952308/ (added 20/02/2024) 2023 Results article in https://pubmed.ncbi.nlm.nih.gov/38109218/ (added 20/02/2024)
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •Current inclusion criteria as of 04/09/2020:
- •1. Adults aged 17 years and above
- •2. Diagnostic and Statistical Manual of Mental Disorders (DSM)-5 diagnosis of severe anorexia nervosa (AN) or related disorder (e.g., avoidant/restrictive food intake disorder [ARFID; where food restriction and weight loss occur in the absence of concerns about shape and weight])
- •3. Body mass index (BMI) equal to or less than 16 kg/m²
- •4. In need for intensive treatment because of either rapid weight loss, and/or evidence of system/organ failure/medical instability and/or unsuccessful outpatient treatment
- •5. Have mental capacity to give informed consent to participate in the study
- •Previous inclusion criteria:
- •1. Male and female adults
- •2. Aged 17 years and above
- •3. Diagnostic and Statistical Manual of Mental Disorders (DSM)-5 diagnosis of severe anorexia nervosa (AN) or related disorder (e.g., avoidant/restrictive food intake disorder [ARFID; where food restriction and weight loss occur in the absence of concerns about shape and weight])
- •4. Body mass index (BMI) of less than 16 kg/m²
- •5. In need for intensive treatment because of either rapid weight loss, and/or evidence of system/organ failure/medical instability and/or unsuccessful outpatient treatment
- •6. Have mental capacity to give informed consent to participate in the study
排除标准
- •Current exclusion criteria as of 04/09/2020:
- •1. Insufficient knowledge of English to complete study assessments or understand treatment
- •2. Severe learning disability
- •3. Severe medical or psychiatric (co)morbidity (e.g. psychosis, substance dependence) needing treatment in its own right
- •4. Those living too far away from day-patient treatment (and where no alternative arrangements for regular attendance at day-patient treatment can be made).
- •Previous exclusion criteria:
- •1. Insufficient knowledge of English to complete study assessments or understand treatment
- •2. Severe learning disability
- •3. Severe medical or psychiatric (co)morbidity (e.g. psychosis, substance dependence) needing treatment in its own right
- •4. Those living too far away from day-patient treatment (and where no alternative arrangements for regular attendance at day-patient treatment can be made).
- •5. Those who are involved in current research or have recently been involved in any research prior to recruitment
研究者
相似试验
已完成
3 期
An open-label, multicenter, randomized, controlled adaptive study to evaluate the efficacy and safety of investigational therapeutics for the treatment of hospitalized patients with mild to moderate novel coronavirus disease (COVID-19) in Kinshasa, Democratic Republic of the CongoISRCTN16254682Creppat Laboratories SAR376
已完成
不适用
A study to examine changes in exposure to cigarette smoke chemicals when a smoker switches to using a tobacco heating productCigarette smokingMental and Behavioural DisordersMental and behavioural disorders due to use of tobaccoISRCTN14301360British American Tobacco (Investments) Ltd180
进行中(未招募)
2 期
Stopping Eculizumab Treatment Safely in atypical Haemolytic Uraemic Syndrome (SETS aHUS)Atypical hemolytic uremic syndromeUrological and Genital DiseasesHaemolytic-uraemic syndromeISRCTN17503205The Newcastle Upon Tyne Hospitals NHS Foundation Trust39
已完成
2 期
The Cardiac CARE Trial – can heart muscle injury related to chemotherapy be prevented?Heart muscle injury in patients receiving chemotherapy for breast cancer or non-Hodgkin lymphomaCirculatory SystemISRCTN24439460ACCORD - University of Edinburgh & NHS Lothian co-sponsors168
已完成
2 期
A Phase II, Open Label, Multicenter Randomised Controlled Trial Comparing Hyperthermia Plus Mitomycin To Mitomycin Alone, In Patients with Intermediate Risk Non-Muscle Invasive Bladder CancerTopic: CancerSubtopic: Bladder CancerDisease: Bladder (advanced), Bladder (superficial)Bladder, unspecifiedCancerISRCTN23639415Queen Mary University of London (UK)259
